Exelixis Shares Outstanding 2006-2019 | EXEL

Exelixis shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Exelixis shares outstanding for the quarter ending March 31, 2019 were 0.315B, a 0.3% increase year-over-year.
  • Exelixis 2018 shares outstanding were 0.313B, a 0.26% increase from 2017.
  • Exelixis 2017 shares outstanding were 0.312B, a 24.54% increase from 2016.
  • Exelixis 2016 shares outstanding were 0.251B, a 19.74% increase from 2015.
Exelixis Annual Shares Outstanding
(Millions of Shares)
2018 313
2017 312
2016 251
2015 209
2014 194
2013 184
2012 160
2011 130
2010 109
2009 107
2008 105
2007 99
2006 87
2005 79
Exelixis Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 315
Q4 2018 313
Q3 2018 312
Q2 2018 312
Q1 2018 314
Q4 2017 312
Q3 2017 313
Q2 2017 311
Q1 2017 310
Q4 2016 251
Q3 2016 256
Q2 2016 229
Q1 2016 228
Q4 2015 209
Q3 2015 218
Q2 2015 196
Q1 2015 196
Q4 2014 194
Q3 2014 195
Q2 2014 195
Q1 2014 192
Q4 2013 184
Q3 2013 184
Q2 2013 184
Q1 2013 184
Q4 2012 160
Q3 2012 166
Q2 2012 149
Q1 2012 142
Q4 2011 130
Q3 2011 131
Q2 2011 128
Q1 2011 113
Q4 2010 109
Q3 2010 109
Q2 2010 108
Q1 2010 108
Q4 2009 107
Q3 2009 107
Q2 2009 107
Q1 2009 106
Q4 2008 105
Q3 2008 106
Q2 2008 105
Q1 2008 105
Q4 2007 99
Q3 2007 99
Q2 2007 97
Q1 2007 96
Q4 2006 87
Q3 2006 84
Q2 2006 84
Q1 2006 84
Q4 2005 79
Q3 2005 80
Q2 2005 76
Q1 2005 76
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.482B $0.854B
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.245B 12.24
Gilead Sciences (GILD) United States $85.342B 10.36
Celgene (CELG) United States $64.552B 10.94
Vertex Pharmaceuticals (VRTX) United States $45.118B 54.54
Biogen (BIIB) United States $44.896B 8.52
Illumina (ILMN) United States $44.438B 51.50
CSL (CSLLY) Australia $35.409B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.605B 15.32
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.541B 15.59
Incyte (INCY) United States $17.129B 69.46
Exact Sciences (EXAS) United States $14.845B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.750B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Sarepta Therapeutics (SRPT) United States $11.364B 0.00
Genmab (GNMSF) Denmark $11.067B 56.26
Array BioPharma (ARRY) United States $10.346B 0.00
Seattle Genetics (SGEN) United States $10.192B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.908B 29.26
Galapagos (GLPG) Belgium $8.802B 0.00
Bio-Techne Corp (TECH) United States $7.964B 54.34
Alnylam Pharmaceuticals (ALNY) United States $7.909B 0.00
Guardant Health (GH) United States $7.720B 0.00
Bluebird Bio (BLUE) United States $7.368B 0.00
Amarin (AMRN) Ireland $7.189B 0.00
BeiGene (BGNE) Cayman Islands $5.652B 0.00
Ascendis Pharma (ASND) Denmark $4.867B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.719B 0.00
Moderna (MRNA) United States $4.652B 0.00
Blueprint Medicines (BPMC) United States $4.628B 0.00
Horizon Pharma Public (HZNP) Ireland $4.408B 11.35
Repligen (RGEN) United States $4.177B 104.05
ACADIA Pharmaceuticals (ACAD) United States $3.787B 0.00
Spark Therapeutics (ONCE) United States $3.752B 0.00
Mirati Therapeutics (MRTX) United States $3.729B 0.00
China Biologic Products (CBPO) China $3.682B 23.39
Alkermes (ALKS) Ireland $3.668B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.401B 0.00
MorphoSys AG (MOR) Germany $3.316B 0.00
Arena Pharmaceuticals (ARNA) United States $3.062B 6.22
Amicus Therapeutics (FOLD) United States $2.899B 0.00
Immunomedics (IMMU) United States $2.772B 0.00
Medicines (MDCO) United States $2.740B 0.00
UniQure (QURE) Netherlands $2.631B 0.00
Reata Pharmaceuticals (RETA) United States $2.613B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.566B 0.00
Halozyme Therapeutics (HALO) United States $2.468B 0.00
MyoKardia (MYOK) United States $2.308B 0.00
Ligand Pharmaceuticals (LGND) United States $2.299B 19.04
Nabriva Therapeutics AG (NBRV) Ireland $2.251B 0.00
Emergent Biosolutions (EBS) United States $2.231B 19.38
NeoGenomics (NEO) United States $2.216B 145.06
Acceleron Pharma (XLRN) United States $2.160B 0.00
Zai Lab (ZLAB) China $2.106B 0.00
Genomic Health (GHDX) United States $2.078B 44.13
Akcea Therapeutics (AKCA) United States $2.072B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.046B 0.00
Denali Therapeutics (DNLI) United States $1.911B 0.00
Myriad Genetics (MYGN) United States $1.907B 18.97
REGENXBIO (RGNX) United States $1.720B 0.00
Insmed (INSM) United States $1.690B 0.00
Cambrex (CBM) United States $1.501B 18.98
Fate Therapeutics (FATE) United States $1.464B 0.00
AnaptysBio (ANAB) United States $1.431B 0.00
RA PHARMCTL INC (RARX) United States $1.421B 0.00
Innoviva (INVA) United States $1.405B 3.89
Sangamo Therapeutics (SGMO) United States $1.349B 0.00
Athenex (ATNX) United States $1.329B 0.00
Alector (ALEC) United States $1.311B 0.00
Coherus BioSciences (CHRS) United States $1.284B 0.00
Editas Medicine (EDIT) United States $1.198B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Epizyme (EPZM) United States $1.174B 0.00
Cara Therapeutics (CARA) United States $1.036B 0.00
Codexis (CDXS) United States $1.031B 0.00
Adverum Biotechnologies (ADVM) United States $1.013B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.013B 0.00
Dicerna Pharmaceuticals (DRNA) United States $0.979B 0.00
ANI Pharmaceuticals (ANIP) United States $0.976B 17.31
Twist Bioscience (TWST) United States $0.963B 0.00
Principia Biopharma (PRNB) United States $0.955B 0.00
Zymeworks (ZYME) Canada $0.940B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.928B 0.00
WAVE Life Sciences (WVE) Singapore $0.924B 0.00
Retrophin (RTRX) United States $0.873B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.873B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.854B 0.00
Arvinas (ARVN) United States $0.811B 0.00
Intellia Therapeutics (NTLA) United States $0.755B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.712B 33.60
Precision BioSciences (DTIL) United States $0.699B 0.00
Zealand Pharma (ZEAL) Denmark $0.683B 7.99
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Clovis Oncology (CLVS) United States $0.678B 0.00
Cytokineticsorporated (CYTK) United States $0.668B 0.00
Cellectis S.A (CLLS) France $0.647B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.640B 0.00
Intra-Cellular Therapies (ITCI) United States $0.640B 0.00
Heska (HSKA) United States $0.617B 63.16
DBV Technologies S.A (DBVT) France $0.604B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.589B 0.00
Anika Therapeutics (ANIK) United States $0.579B 19.79
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.575B 0.00
Stemline Therapeutics (STML) United States $0.568B 0.00
MiMedx (MDXG) United States $0.546B 0.00
Revance Therapeutics (RVNC) United States $0.542B 0.00
CytomX Therapeutics (CTMX) United States $0.537B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.504B 0.00
PHARMA MAR SA (PHMMF) Spain $0.454B 0.00
UROGEN PHARMA (URGN) United States $0.447B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.417B 0.00
Prothena (PRTA) Ireland $0.386B 0.00
Biofrontera AG (BFRA) Germany $0.385B 0.00
PDL BioPharma (PDLI) United States $0.379B 9.06
AC Immune SA (ACIU) Switzerland $0.377B 24.26
Arcus Biosciences (RCUS) United States $0.376B 0.00
Gritstone Oncology (GRTS) United States $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Bellus Health (BLUSF) Canada $0.366B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.365B 0.00
Scholar Rock Holding (SRRK) United States $0.359B 0.00
Avid Bioservices (CDMO) United States $0.359B 0.00
Merus (MRUS) Netherlands $0.359B 0.00
Starpharma Holdings (SPHRY) Australia $0.356B 0.00
Prometic Life Sciences (PFSCD) Canada $0.348B 0.00
Albireo Pharma (ALBO) United States $0.346B 0.00
Agenus (AGEN) United States $0.344B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.343B 0.00
BioDelivery Sciences (BDSI) United States $0.340B 0.00
Senesco Technologies (ELOX) United States $0.337B 0.00
Acorda Therapeutics (ACOR) United States $0.331B 5.83
Kadmon Holdings (KDMN) United States $0.329B 0.00
Theratechnologies (THERF) Canada $0.328B 0.00
Syros Pharmaceuticals (SYRS) United States $0.324B 0.00
Protagonist Therapeutics (PTGX) United States $0.309B 0.00
Sorrento Therapeutics (SRNE) United States $0.308B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.304B 0.00
Inovio Pharmaceuticals (INO) United States $0.294B 0.00
Cellular Biomedicine (CBMG) United States $0.270B 0.00
Kindred Biosciences (KIN) United States $0.269B 0.00
PHASEBIO PHARMA (PHAS) United States $0.263B 0.00
ChromaDex (CDXC) United States $0.262B 0.00
Sutro Biopharma (STRO) United States $0.261B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.260B 0.00
Dynavax Technologies (DVAX) United States $0.252B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.247B 0.00
Kamada (KMDA) Israel $0.238B 9.22
ADMA Biologics Inc (ADMA) United States $0.233B 0.00
Athersys (ATHX) United States $0.232B 0.00
Geron (GERN) United States $0.226B 0.00
Palatin Technologies (PTN) United States $0.222B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.221B 0.00
Cel-Sci (CVM) United States $0.220B 0.00
Cerecor (CERC) United States $0.210B 0.00
MannKind (MNKD) United States $0.205B 0.00
Five Prime Therapeutics (FPRX) United States $0.204B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.198B 0.00
CorMedix Inc (CRMD) United States $0.198B 0.00
Abeona Therapeutics (ABEO) United States $0.196B 0.00
Synlogic (SYBX) United States $0.195B 0.00
Mersana Therapeutics (MRSN) United States $0.191B 0.00
Affimed (AFMD) Germany $0.191B 0.00
OSMOTICA PHARM (OSMT) United States $0.186B 0.00
Pfenex (PFNX) United States $0.186B 0.00
Spero Therapeutics (SPRO) United States $0.185B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Arsanis (XFOR) United States $0.183B 0.00
Compugen (CGEN) Israel $0.182B 0.00
Enzo Biochem (ENZ) United States $0.178B 0.00
BioTime (BTX) United States $0.177B 11.80
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.163B 0.00
XOMA (XOMA) United States $0.158B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.157B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.63
OvaScience (MLND) United States $0.148B 0.00
Cue Biopharma (CUE) United States $0.148B 0.00
TOCAGEN INC (TOCA) United States $0.142B 0.00
Liquidia Technologies (LQDA) United States $0.140B 0.00
Adocia (ADOCY) France $0.140B 0.00
Celyad SA (CYAD) Belgium $0.140B 0.00
Northwest Biotherapeutics (NWBO) United States $0.135B 0.00
Dyadic (DYAI) United States $0.134B 0.00
NantKwest (NK) United States $0.127B 0.00
Seres Therapeutics (MCRB) United States $0.125B 0.00
Aptinyx (APTX) United States $0.123B 0.00
Alcobra (ARCT) United States $0.120B 0.00
Arbutus Biopharma (ABUS) Canada $0.119B 0.00
Aduro Biotech (ADRO) United States $0.119B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.119B 0.00
Menlo Therapeutics (MNLO) United States $0.118B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.117B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.116B 0.00
Verastem (VSTM) United States $0.114B 0.00
Novavax (NVAX) United States $0.109B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.103B 0.00
Checkpoint Therapeutics (CKPT) United States $0.103B 0.00
SESEN BIO, INC (SESN) United States $0.100B 0.00
Trevena (TRVN) United States $0.097B 0.00
Curis (CRIS) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.093B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.085B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Pluristem Therapeutics (PSTI) Israel $0.084B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.083B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.083B 0.00
VBI Vaccines (VBIV) United States $0.082B 0.00
AquaBounty Technologies (AQB) United States $0.081B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VTv Therapeutics (VTVT) United States $0.078B 0.00
Selecta Biosciences (SELB) United States $0.075B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.073B 0.00
Idera Pharmaceuticals (IDRA) United States $0.073B 0.00
Signal Genetics (MGEN) United States $0.072B 0.00
Orgenesis (ORGS) United States $0.072B 0.00
Applied Genetic Technologies (AGTC) United States $0.069B 37.90
Organovo Holdings (ONVO) United States $0.067B 0.00
ARAVIVE, INC (ARAV) United States $0.063B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Protalix BioTherapeutics (PLX) Israel $0.060B 0.00
Antibe Therapeutics (ATBPF) Canada $0.060B 0.00
Prima BioMed (IMMP) Australia $0.059B 0.00
Invo BioScience (IVOB) United States $0.057B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.053B 0.00
Ophthotech (ISEE) United States $0.051B 0.00
Proteostasis Therapeutics (PTI) United States $0.050B 0.00